1. Home
  2. ACHR vs GRFS Comparison

ACHR vs GRFS Comparison

Compare ACHR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Archer Aviation Inc.

ACHR

Archer Aviation Inc.

HOLD

Current Price

$8.47

Market Cap

5.7B

Sector

Industrials

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.81

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACHR
GRFS
Founded
2018
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
6.2B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
ACHR
GRFS
Price
$8.47
$8.81
Analyst Decision
Buy
Hold
Analyst Count
7
2
Target Price
$12.14
$10.15
AVG Volume (30 Days)
36.5M
442.6K
Earning Date
02-26-2026
07-28-2022
Dividend Yield
N/A
1.56%
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
N/A
$8,821,017,248.00
Revenue This Year
N/A
$5.36
Revenue Next Year
N/A
$5.15
P/E Ratio
N/A
$17.98
Revenue Growth
N/A
7.31
52 Week Low
$5.48
$6.19
52 Week High
$14.62
$11.14

Technical Indicators

Market Signals
Indicator
ACHR
GRFS
Relative Strength Index (RSI) 51.80 41.49
Support Level $8.42 $9.17
Resistance Level $9.24 $9.57
Average True Range (ATR) 0.44 0.22
MACD 0.11 -0.03
Stochastic Oscillator 58.97 5.13

Price Performance

Historical Comparison
ACHR
GRFS

About ACHR Archer Aviation Inc.

Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: